Telomir Pharmaceuticals, Inc. (Nasdaq:TELO)
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm’s initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.
100 SE 2nd Street
Suite 2000-1009
Miami, Florida 33131
9
$4.1300
4.0100 - 4.4500
3.1100 - 9.3900
191.94K
1.72M (02/14/25)
9.99%
$122.92M
N/A
-$13.07M
N/A
Chairman & Chief Executive Officer Erez Aminov |
Director Matthew P. Del Giudice |
Director Edward MacPherson |
Director Matthew Pratt Whalen |
Independent Director Craig Eagle |
Date | Form | Event |
---|---|---|
20 Dec, 2024 | 8-K | |
11 Dec, 2024 | 8-K | |
2 Dec, 2024 | 8-K | |
25 Nov, 2024 | 4 | |
21 Nov, 2024 | 8-K | |
20 Nov, 2024 | 8-K | |
12 Nov, 2024 | 10-Q | |
27 Sep, 2024 | 8-K | |
4 Sep, 2024 | 4 | |
3 Sep, 2024 | 8-K | |
29 Aug, 2024 | 4 | |
29 Aug, 2024 | 4 | |
29 Aug, 2024 | 4 | |
29 Aug, 2024 | 3 | |
29 Aug, 2024 | 4 | |
29 Aug, 2024 | 4 | |
15 Aug, 2024 | 3 | |
15 Aug, 2024 | 3 | |
15 Aug, 2024 | 3 | |
15 Aug, 2024 | 3 | |
13 Aug, 2024 | 10-Q | |
24 Jun, 2024 | 8-K | |
13 May, 2024 | 10-Q | |
15 Apr, 2024 | 8-K | |
12 Apr, 2024 | 8-K | |
29 Mar, 2024 | 10-K | |
15 Feb, 2024 | 4 | |
13 Feb, 2024 | 8-K | |
12 Feb, 2024 | 424B1 | IPO completed |
12 Feb, 2024 | 424B4 | |
8 Feb, 2024 | 3 | |
8 Feb, 2024 | 3 | |
8 Feb, 2024 | 3 | |
8 Feb, 2024 | 3 | |
8 Feb, 2024 | 3 | |
8 Feb, 2024 | EFFECT | |
8 Feb, 2024 | CERT | |
8 Feb, 2024 | 3 | |
8 Feb, 2024 | 3 | |
8 Feb, 2024 | 3 | |
8 Feb, 2024 | 3 | |
6 Feb, 2024 | CORRESP | |
6 Feb, 2024 | CORRESP | |
6 Feb, 2024 | 8-A12B | |
3 Jan, 2024 | S-1/A | |
3 Jan, 2024 | CORRESP | |
19 Dec, 2023 | S-1/A | |
19 Dec, 2023 | UPLOAD | |
14 Dec, 2023 | S-1/A | |
14 Dec, 2023 | CORRESP | |
28 Nov, 2023 | UPLOAD | |
14 Nov, 2023 | S-1 | |
13 Nov, 2023 | CORRESP | |
1 Nov, 2023 | UPLOAD | |
16 Oct, 2023 | DRSLTR | |
16 Oct, 2023 | DRS/A | |
18 Sep, 2023 | UPLOAD | |
14 Aug, 2023 | DRS | |
3 Apr, 2023 | D |
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.